Essential articles: Surgical oncology

Emory users, open this instance of PubMed, then click the links below for full-text article access.

Abdominal (Malignant):

Al-Batran SE, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial Lancet. 2019 May 11;393(10184):1948-1957. doi: 10.1016/S0140-6736(18)32557-1.   

Shapiro J, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial Lancet Oncol. 2015 Sep;16(9):1090-1098. doi: 10.1016/S1470-2045(15)00040-6.   

Degiuli M, et al. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer Br J Surg. 2014 Jan;101(2):23-31. doi: 10.1002/bjs.9345. 

Bang YJ, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet. 2010 Aug 28;376(9742):687-97. doi: 10.1016/S0140-6736(10)61121-X.   

Continue reading

ASO Landmark Series

Emory users, open this instance of PubMed, then click the links below for full-text article access.

McMasters KM. Introducing: The Landmark Series. Ann Surg Oncol. 2020 Jan;27(1):1-2.

The Annals of Surgical Oncology, the journal of the Society of Surgical Oncology, has created The Landmark Article Series.

“The Landmark Series is designed to trace the origins of current multidisciplinary therapy for each type of solid tumor, and demonstrate the logical progression of clinical trials and other key evidence. It is meant to be an educational resource, for trainees and practicing cancer specialists alike, in the understanding of evidence-based cancer management. Practice-changing clinical trials and other key evidence that inform our current treatment guidelines will be summarized and reviewed. Expert authors will provide context and commentary to enhance the value to the reader.” (McMasters, p.1).


Beasley GM, et al. The Landmark Series: Regional Therapy of Recurrent Cutaneous Melanoma. Ann Surg Oncol. 2020 Jan;27(1):35-42.

Egger ME, et al. The Sunbelt Melanoma Trial. Ann Surg Oncol. 2020 Jan;27(1):28-34.

Bello DM, Faries MB. The Landmark Series: MSLT-1, MSLT-2 and DeCOG
(Management of Lymph Nodes)
. Ann Surg Oncol. 2020 Jan;27(1):15-21.

Continue reading